The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Amjevita
adalimumab-atto · ADALIMUMAB 80 mg/.8mL · Injection · Subcutaneous · Amgen, Inc
NDC 55513-0481-01 · 1 SYRINGE in 1 CARTON / .8 mL in 1 SYRINGE · BLA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 55513-0481-02) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$749.47per unit
middle half $749.47–$1,705.36 · 148 plans · Apr 1, 2026
Est. net of rebatesⓘ
$449.68–$562.10
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
3%of plans cover it
tier 3 · prior auth 22% · step therapy 0% · qty limit 18%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$1,385.22
Reported to Texas DSHS · 2026 annual filing · Amgen Usa Inc
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicaid spend (2025)
$971,555
355 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Is this a "specialty" drug?
There's no legal definition — it meets 3 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $1,632.63 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- BLA761024
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of adalimumab-atto (Injection)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Amgen USA Inc. | ADALIMUMAB 40 mg/.4mL | Jul 15, 2026 | Sep 3, 2026 |
| Amgen, Inc | ADALIMUMAB 80 mg/.8mL | Jul 15, 2026 | Sep 3, 2026 |
| Amgen, Inc | ADALIMUMAB 40 mg/.4mL | Jul 15, 2026 | Sep 3, 2026 |
| Amgen USA Inc. | ADALIMUMAB 80 mg/.8mL | Jul 15, 2026 | Sep 2, 2026 |
| Amgen USA Inc. | ADALIMUMAB 20 mg/.2mL | Jul 15, 2026 | Sep 2, 2026 |
| Amgen USA Inc. | ADALIMUMAB 40 mg/.8mL | Jul 15, 2026 | Sep 2, 2026 |
| Amgen, Inc | ADALIMUMAB 10 mg/.2mL | Jul 15, 2026 | Sep 2, 2026 |
| Amgen, Inc | ADALIMUMAB 20 mg/.2mL | Jul 15, 2026 | Sep 2, 2026 |
| Amgen, Inc | ADALIMUMAB 20 mg/.4mL | Jul 15, 2026 | Sep 2, 2026 |
| Nuvaila Limited | ADALIMUMAB 80 mg/.8mL | Jul 15, 2026 | Sep 2, 2026 |
| Nuvaila Limited | ADALIMUMAB 20 mg/.2mL | Jul 15, 2026 | Sep 2, 2026 |
| Nuvaila Limited | ADALIMUMAB 40 mg/.4mL | Jul 15, 2026 | Aug 31, 2026 |
| Amgen, Inc | ADALIMUMAB 40 mg/.8mL | Jul 15, 2026 | Aug 28, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Amjevita — NDC 55513-0481-01," retrieved September 3, 2026, https://drugdashboards.com/drug/55513048101.
Free to cite with attribution — see how the data is put together.